ALK,Alaska Air to form codeshare deal with Japan Airlines May 10 Alaska Air Group Inc on Tuesday announced plans for a codeshare agreement and a frequent flier partnership with Japan Airlines Co Ltd. 
ALB,BRIEF-Albemarle names David Ryan treasurer * Albemarle names David Ryan treasurer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780) 
AGN,BRIEF-Adamis Pharmaceuticals announces license agreement with Allergan unitBRIEF-Allergan announces share repurchase program of up to $10 blnAllergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)       Allergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      * Company expects to execute $4 - $5 billion in open market repurchasesAllergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)        BRIEF-Allergan announces share repurchase program of up to $10 blnAllergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)       Allergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      * Company expects to execute $4 - $5 billion in open market repurchasesAllergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)       * Watson will obtain commercial rights for U.S. For upfront fee and milestone payments totaling up to $32.5 millionBRIEF-Allergan announces share repurchase program of up to $10 blnAllergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)       Allergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      * Company expects to execute $4 - $5 billion in open market repurchasesAllergan reports 48 pct rise in quarterly revenueBRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)      BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis.BRIEF-Allergan Q1 loss per share $0.38 from continuing operationsBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)     BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    * Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IRBRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)    BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   * Supernus enters into partial settlement agreement with Actavis on oxtellar xrBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)   BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialBRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceedsUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)  UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) * Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potentialUPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price)        
AMZN,UPDATE 2-Amazon takes aim at YouTube with new video serviceUS STOCKS-Wall St rallies, led by financials, energy stocks and AmazonUS STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.   US STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  * Indexes up: Dow 0.98 pct, S&P; 0.89 pct, Nasdaq 0.69 pct   (Adds details, changes comment, updates prices.)US STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.    US STOCKS-Wall St rallies, led by financials, energy stocks and AmazonUS STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.   US STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  * Indexes up: Dow 0.98 pct, S&P; 0.89 pct, Nasdaq 0.69 pct   (Adds details, changes comment, updates prices.)US STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.   May 10 Amazon.com Inc launched a service on Tuesday that allows users to post videos and earn royalties from them, setting up the world's biggest online retailer to compete directly with Alphabet Inc's  YouTube.US STOCKS-Wall St rallies, led by financials, energy stocks and AmazonUS STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.   US STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  * Indexes up: Dow 0.98 pct, S&P; 0.89 pct, Nasdaq 0.69 pct   (Adds details, changes comment, updates prices.)US STOCKS-Amazon puts Wall St on track for best day in a monthUS STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.  US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months. * Indexes up: Dow 1.06 pct, S&P; 1.06 pct, Nasdaq 1.03 pct   (Updates with afternoon trade)US STOCKS SNAPSHOT-S&P; 500 has best day in 2 months; Amazon a boost NEW YORK, May 10 U.S. stocks ended sharply higher on Tuesday, with a rally in Amazon.com helping propel the S&P; 500 to its best day in two months.    
AAPL,BRIEF-Apple pay now available to Canadian Mastercard cardholdersJapan Display warns of bigger year-on-year loss on slow iPhone sales TOKYO, May 10 Apple Inc supplier Japan Display Inc warned on Tuesday of a bigger loss in the just-ended business year compared to the previous year as sluggish demand for iPhones dragged down sales of its display panels.  Japan Display warns of bigger year-on-year loss on slow iPhone sales TOKYO, May 10 Apple Inc supplier Japan Display Inc warned on Tuesday of a bigger loss in the just-ended business year compared to the previous year as sluggish demand for iPhones dragged down sales of its display panels. May 10 Mastercard Inc : * Apple pay now available to Canadian Mastercard cardholders Source text for Eikon: Further company coverage:    ) Japan Display warns of bigger year-on-year loss on slow iPhone sales TOKYO, May 10 Apple Inc supplier Japan Display Inc warned on Tuesday of a bigger loss in the just-ended business year compared to the previous year as sluggish demand for iPhones dragged down sales of its display panels.  
BA,UPDATE 3-Machinists vote to strike at Triumph plant supplying Boeing, AirbusMachinists vote to strike at Triumph plant supplying Boeing, AirbusUPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing.  UPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing. SEATTLE Machinists at a Triumph Group factory that supplies parts for Boeing, Airbus and other aircraft makers voted on Monday to strike after rejecting the company's latest labor contract, the union said.UPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing.   Machinists vote to strike at Triumph plant supplying Boeing, AirbusUPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing.  UPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing. SEATTLE Machinists at a Triumph Group factory that supplies parts for Boeing, Airbus and other aircraft makers voted on Monday to strike after rejecting the company's latest labor contract, the union said.UPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing.  SEATTLE, May 9 Machinists at a Triumph Group  factory that supplies parts for Boeing, Airbus  and other aircraft makers voted on Monday to strike after rejecting the company's latest labor contract, the union said.Machinists vote to strike at Triumph plant supplying Boeing, AirbusUPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing.  UPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing. SEATTLE Machinists at a Triumph Group factory that supplies parts for Boeing, Airbus and other aircraft makers voted on Monday to strike after rejecting the company's latest labor contract, the union said.UPDATE 1-Airbus delivery logjam continues, but orders recover in April PARIS, May 10 Airbus continued to be hampered by slow deliveries of its latest models of jets in April, handing over just one A320neo aircraft to Indian budget carrier IndiGo and delivering two long-haul A350 aircraft to remain well behind rival Boeing.   
CBS,New lawsuit alleges paid informants, pricey escort at Redstone mansionBRIEF-Board members from CBS,Viacom planning to visit Redstone to investigate his competency for themselves - WSJ, citing sources * Board members from CBS, Viacom planning to visit Redstone to investigate his competency for themselves, now that trial is over - WSJ, citing sources  Source text - (http://on.wsj.com/1VR4A2v) Further company coverage:    (Bengaluru Newsroom)  BRIEF-Board members from CBS,Viacom planning to visit Redstone to investigate his competency for themselves - WSJ, citing sources * Board members from CBS, Viacom planning to visit Redstone to investigate his competency for themselves, now that trial is over - WSJ, citing sources  Source text - (http://on.wsj.com/1VR4A2v) Further company coverage:    (Bengaluru Newsroom) LOS ANGELES Even as a Los Angeles judge dismissed one case brought by a former girlfriend of media mogul Sumner Redstone, she filed a new lawsuit that threatens to keep salacious allegations about the 92-year-old's lifestyle alive.BRIEF-Board members from CBS,Viacom planning to visit Redstone to investigate his competency for themselves - WSJ, citing sources * Board members from CBS, Viacom planning to visit Redstone to investigate his competency for themselves, now that trial is over - WSJ, citing sources  Source text - (http://on.wsj.com/1VR4A2v) Further company coverage:    (Bengaluru Newsroom)  
CNP,BRIEF-Centerpoint Energy qtrly earnings per share $0.36BRIEF-Centerpoint Energy reaffirms full year EPS guidance of $1.12-$1.20 * Says reaffirms full year earnings per share guidance of $1.12 to $1.20  BRIEF-Centerpoint Energy reaffirms full year EPS guidance of $1.12-$1.20 * Says reaffirms full year earnings per share guidance of $1.12 to $1.20 * Q1 earnings per share view $0.31, revenue view $2.44 billion -- Thomson Reuters I/B/E/S  Source text for Eikon: (http://1.usa.gov/1Yjo4KV) Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)BRIEF-Centerpoint Energy reaffirms full year EPS guidance of $1.12-$1.20 * Says reaffirms full year earnings per share guidance of $1.12 to $1.20  
C,MOVES-Citigroup names new heads of US high yield and loan trading NEW YORK, May 10 (Reuters LPC) - Citigroup has named Faraz Naseer head of US high-yield trading, and Fran Sutter and Michael Schechter co-heads of US loan trading, sources said. 
COP,Conoco CEO looks at hedging options but says market limited HOUSTON, May 10 ConocoPhillips has looked at using derivatives to lock in oil prices in a volatile market, including so-called floors to guard against any new price drops, but Chief Executive Ryan Lance said on Tuesday the company is too big to hedge all of its output. 
CVS,UPDATE 5-Allergan profit beats estimates, share buybacks planned * Shares up 2.9 pct at $220.00   (Adds Breakingviews link, updates share price) 
EA,Electronic Arts profit, revenue beat estimatesBRIEF-Electronic Arts Q4 non-GAAP earnings per share $0.50 * Q4 non-GAAP earnings per share $0.50  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  BRIEF-Electronic Arts Q4 non-GAAP earnings per share $0.50 * Q4 non-GAAP earnings per share $0.50  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) May 10 Video game publisher Electronic Arts Inc , known for titles such as "FIFA" and "Battlefield", reported quarterly revenue and profit above estimates, driven in part by its "Star Wars Battlefront" game.BRIEF-Electronic Arts Q4 non-GAAP earnings per share $0.50 * Q4 non-GAAP earnings per share $0.50  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  
XOM,Saudi Aramco says in final stages of preparing IPO options DHAHRAN, May 10 Saudi Aramco is in the final statges of preparing options for its initial public offer of shares before presenting the options soon to its Supreme Council for consideration, chief executive Amin Nasser said on Tuesday. 
FB,BRIEF-U.S. Senate Commerce Commtitte chair sends letter to Facebook's Zuckerberg  - CNBCBRIEF-"Today we're partnering with Airtel Africa to launch Internet.org in Nigeria"- Zuckerberg in Facebook postUPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list.  UPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list. * "Today we're partnering with Airtel Africa to launch Internet.org Free Basics in Nigeria" - Mark Zuckerberg in Facebook post   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)UPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list.   BRIEF-"Today we're partnering with Airtel Africa to launch Internet.org in Nigeria"- Zuckerberg in Facebook postUPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list.  UPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list. * "Today we're partnering with Airtel Africa to launch Internet.org Free Basics in Nigeria" - Mark Zuckerberg in Facebook post   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)UPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list.  * U.S. Senate Commerce Commtitte chair sends letter to Facebook's Mark Zuckerberg seeking answers on alleged manipulation of trending news - CNBC   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)BRIEF-"Today we're partnering with Airtel Africa to launch Internet.org in Nigeria"- Zuckerberg in Facebook postUPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list.  UPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list. * "Today we're partnering with Airtel Africa to launch Internet.org Free Basics in Nigeria" - Mark Zuckerberg in Facebook post   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)UPDATE 2-U.S. Senate committee questions Facebook over news selection May 10 A U.S. Senate committee launched an inquiry on Tuesday into how social media website Facebook selects its news stories after a report that company employees blocked news about conservative issues from its "trending" list.   
FCX,Freeport to sell prized Tenke copper mine to China Moly for $2.65 billionBRIEF-Lundin Mining gets notice of first offer right on Tenke FungurumeBRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."     BRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    * Lundin Mining receives notice of right of first offer on Tenke FungurumeBRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."      BRIEF-Lundin Mining gets notice of first offer right on Tenke FungurumeBRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."     BRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    * Lundin Mining receives notice of right of first offer on Tenke FungurumeBRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."     Freeport-McMoRan Inc has agreed to sell its majority stake in the Tenke copper project in the Democratic Republic of Congo to China Molybdenum Co Ltd (CMOC) for $2.65 billion in cash, reducing the U.S. miner's debt and handing the Chinese company one of the world's prized copper assets.BRIEF-Lundin Mining gets notice of first offer right on Tenke FungurumeBRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."     BRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    * Lundin Mining receives notice of right of first offer on Tenke FungurumeBRIEF-Noble corporation announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."    Miner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   * Noble Corporation Plc announces agreement with Freeport-McmoranMiner Freeport wants to get debt down to $10 bln in two yearsUPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."   UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  May 10 U.S. miner Freeport-McMoRan Inc  would like to get its debt down to $10 billion over the next two years and is in a series of discussions about selling more of its assets, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Freeport eyes more asset sale to cut debt by halfUPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."  UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights." May 10 Freeport-McMoRan Inc is in talks to sell more assets as it looks to cut its debt by half over the next two years, Chief Executive Richard Adkerson said on Tuesday.UPDATE 1-Congo state miner says not informed of Freeport's copper mine sale KINSHASA, May 10 Democratic Republic of Congo state miner Gecamines said on Tuesday it was not informed of Freeport-McMoRan Inc's sale of its majority stake in the Tenke copper project and "will assert its rights."      
GPS,US STOCKS-Wall St rallies, led by financials, energy stocks and AmazonGap fails to deliver in key spring season, shares slideUS STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.    US STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   May 10 Shares of Gap Inc slumped 13 percent to a more than four-year low on Tuesday after fewer shoppers visiting the company's stores in the key spring season resulted in a steep decline in comparable-store sales.US STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.     Gap fails to deliver in key spring season, shares slideUS STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.    US STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   May 10 Shares of Gap Inc slumped 13 percent to a more than four-year low on Tuesday after fewer shoppers visiting the company's stores in the key spring season resulted in a steep decline in comparable-store sales.US STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.    * Indexes up: Dow 0.98 pct, S&P; 0.89 pct, Nasdaq 0.69 pct   (Adds details, changes comment, updates prices.)Gap fails to deliver in key spring season, shares slideUS STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.    US STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   May 10 Shares of Gap Inc slumped 13 percent to a more than four-year low on Tuesday after fewer shoppers visiting the company's stores in the key spring season resulted in a steep decline in comparable-store sales.US STOCKS-Wall St on track for best one-day gain in a monthU.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.   U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  * Indexes up: Dow 1.1 pct, S&P; 1.01 pct, Nasdaq 1.03 pct   (Updates to early afternoon)U.S. RESEARCH ROUNDUP-Aflac, St. Jude Medical, GapUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.  UPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer. May 10 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Your Community Bankshares, Kohls and Nordic American Tanker, on Tuesday.            HIGHLIGHTS      * Aflac Inc        : FBR cuts to market perform rating        * Sprouts Farmers market Inc        : Goldman Sachs cuts to sell from neutral        * Hasbro Inc        : Piper Jaffray cuts to neutral from overweight           * St. Jude Medical Inc        : SunTrustUPDATE 1-Nothing to fill the Gap: Shares slide as spring sales disappoint May 10 Gap Inc CEO Art Peck had called the spring selling season the company's "no excuses moment", urging investors to be patient as he worked to revive sales at the apparel retailer.     
LMT,BRIEF-GP Strategies receives contracts from Lockheed Martin's aerospace & defense unitU.S. Air Force sets stage for three-way contest to build new GPS satellites CAPE CANAVERAL, Fla., May 10 The U.S. Air Force has set the stage for a three-way contest to build its GPS 3 satellites, giving rivals Boeing Co and Northrop Grumman Corp a chance to wrest work worth billions of dollars away from Lockheed Martin Corp.  U.S. Air Force sets stage for three-way contest to build new GPS satellites CAPE CANAVERAL, Fla., May 10 The U.S. Air Force has set the stage for a three-way contest to build its GPS 3 satellites, giving rivals Boeing Co and Northrop Grumman Corp a chance to wrest work worth billions of dollars away from Lockheed Martin Corp. * Lockheed Martin's aerospace & defense business has awarded two 3-year contracts to GP Strategies to be their learning services partner  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)U.S. Air Force sets stage for three-way contest to build new GPS satellites CAPE CANAVERAL, Fla., May 10 The U.S. Air Force has set the stage for a three-way contest to build its GPS 3 satellites, giving rivals Boeing Co and Northrop Grumman Corp a chance to wrest work worth billions of dollars away from Lockheed Martin Corp.  
MRO,BRIEF-United States Steel Corp announces tender offers for up to $500 mln of senior notes * Tender offers to purchase up to a total of $500 million aggregate principal amount of its outstanding 7.000% senior notes due 2018 
MSFT,Marketo working with Morgan Stanley for potential sale - Bbg May 10 Marketo Inc, a maker of cloud-based marketing software, is working with Morgan Stanley to explore strategic alternatives including a potential sale, Bloomberg reported, citing people with knowledge of the matter. 
MON,BRIEF-Monsanto continues to expect to hold or grow corn share in U.S. in 2016 * Across Europe and South Africa, company also continues to expect to hold or grow share in a region of declining corn acres 
MS,Morgan Stanley commodities group moving to Times Square after 15 years in suburbiaMorgan Stanley commodities group moving to Times Square after 15 years in suburbia Morgan Stanley is moving its commodities trading business, which has been housed in Purchase, New York, for the last 15 years, to the bank's Times Square headquarters.  Morgan Stanley commodities group moving to Times Square after 15 years in suburbia Morgan Stanley is moving its commodities trading business, which has been housed in Purchase, New York, for the last 15 years, to the bank's Times Square headquarters. May 10 Morgan Stanley is moving its commodities trading business, which has been housed in Purchase, New York, for the last 15 years, to the bank's Times Square headquarters.Morgan Stanley commodities group moving to Times Square after 15 years in suburbia Morgan Stanley is moving its commodities trading business, which has been housed in Purchase, New York, for the last 15 years, to the bank's Times Square headquarters.  
ORCL,Oracle paints Google as unfair competitor in retrial over AndroidUPDATE 2-Google, Oracle compete for innovation label in Android retrialGoogle, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video   Google, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video  SAN FRANCISCO, May 10 Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator.Google, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video    UPDATE 2-Google, Oracle compete for innovation label in Android retrialGoogle, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video   Google, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video  SAN FRANCISCO, May 10 Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator.Google, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video   SAN FRANCISCO, May 10 An attorney for Oracle Corp told jurors on Tuesday that Alphabet Inc's  Google deliberately took Oracle's intellectual property without permisson, kicking off a $9 billion retrial.UPDATE 2-Google, Oracle compete for innovation label in Android retrialGoogle, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video   Google, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video  SAN FRANCISCO, May 10 Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator.Google, Oracle compete for innovation label in Android retrial SAN FRANCISCO Oracle Corp and Google faced off on Tuesday in a $9 billion copyright retrial, with Oracle accusing Google of stealing programming to become the world's leading smartphone player and Google saying it acted legally as a true innovator. | Video    
PFE,Allergan reports 48 pct rise in quarterly revenue May 10 Allergan Plc, whose $160 billion merger with Pfizer Inc fell apart last month, reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business, which includes Botox and the eye drug Restasis. 
SPLS,BRIEF-Staples and Office Depot to terminate merger agreementUPDATE 2-Staples, Office Depot to scrap merger deal after judge rules for FTCStaples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns.  Staples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns. * Office Depot shares plunge 26 pct; Staples shares down 10 pctStaples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns.   UPDATE 2-Staples, Office Depot to scrap merger deal after judge rules for FTCStaples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns.  Staples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns. * Office Depot shares plunge 26 pct; Staples shares down 10 pctStaples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns.  * Says exploring strategic alternatives for European operationsUPDATE 2-Staples, Office Depot to scrap merger deal after judge rules for FTCStaples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns.  Staples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns. * Office Depot shares plunge 26 pct; Staples shares down 10 pctStaples, Office Depot to scrap merger deal after judge rules for FTC WASHINGTON No. 1 office supply chain Staples  and smaller rival Office Depot Inc said on Tuesday they would terminate their planned merger after a U.S. federal judge ordered the deal temporarily halted because of antitrust concerns.   
KO,South Africa's antitrust authority conditionally approves SABMiller, Coke bottling dealUPDATE 2-South Africa approves SABMiller, Coke bottling deal with conditions * Transaction to complete as soon as practicable   (Adds comment from Coca-Cola and Gutsche)  UPDATE 2-South Africa approves SABMiller, Coke bottling deal with conditions * Transaction to complete as soon as practicable   (Adds comment from Coca-Cola and Gutsche) JOHANNESBURG, May 10 South Africa's Competition Tribunal on Tuesday conditionally approved a merger between SABMiller and Coca-Cola to merge African soft drink operations into what would be the continent's biggest Coke drinks bottler.UPDATE 2-South Africa approves SABMiller, Coke bottling deal with conditions * Transaction to complete as soon as practicable   (Adds comment from Coca-Cola and Gutsche)  
DIS,Disney's 2nd-qtr revenue rises 4.1 pctBRIEF-Walt Disney CEO says no plans currently to extend his contract beyond June 2018- Conf callUPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected.  UPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected. * CEO Iger says no plans currently to extend his contract beyond June 2018 - Conf callUPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected.   BRIEF-Walt Disney CEO says no plans currently to extend his contract beyond June 2018- Conf callUPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected.  UPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected. * CEO Iger says no plans currently to extend his contract beyond June 2018 - Conf callUPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected.  May 10 Walt Disney Co's reported a 4.1 percent rise in quarterly revenue, helped by the box-office success of "Star Wars: The Force Awakens" and animated movie "Zootopia".BRIEF-Walt Disney CEO says no plans currently to extend his contract beyond June 2018- Conf callUPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected.  UPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected. * CEO Iger says no plans currently to extend his contract beyond June 2018 - Conf callUPDATE 3-Disney reports rare earnings miss, shares sink May 10 Walt Disney Co, an investor favorite for consistently beating Wall Street earnings targets, reported a rare miss on Tuesday as advertising and subscriptions declined at sports channel ESPN and theme park revenue came in weaker than expected.   
TSN,Brazil's BRF may be in Tyson's expansion plans -paper SAO PAULO, May 10 Executives of Tyson Foods , the largest U.S. meats company that plans to resume investment abroad, have been visiting plants of Brazil's poultry processor BRF SA over the past month, the Valor Economico newspaper said on Tuesday. 
VZ,Verizon and ESPN reach settlement in Fios pay-TV lawsuitUPDATE 1-Verizon, ESPN reach settlement in Fios pay-TV lawsuitVerizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.  Verizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package. NEW YORK, May 10 Verizon Communications Inc  said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.Verizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.   UPDATE 1-Verizon, ESPN reach settlement in Fios pay-TV lawsuitVerizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.  Verizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package. NEW YORK, May 10 Verizon Communications Inc  said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.Verizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.  NEW YORK, May 10 Verizon Communications Inc  said on Tuesday it has reached a  settlement with ESPN in a lawsuit over its Fios pay-TV offering.UPDATE 1-Verizon, ESPN reach settlement in Fios pay-TV lawsuitVerizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.  Verizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package. NEW YORK, May 10 Verizon Communications Inc  said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.Verizon, ESPN reach settlement in Fios pay-TV lawsuit NEW YORK Verizon Communications Inc said on Tuesday it has reached a settlement with ESPN in a lawsuit over the slimmed-down Verizon-Fios pay-TV offering that had left the sports channel out of the basic package.   
VIAB,BRIEF-Board members from CBS,Viacom planning to visit Redstone to investigate his competency for themselves - WSJ, citing sources * Board members from CBS, Viacom planning to visit Redstone to investigate his competency for themselves, now that trial is over - WSJ, citing sources  Source text - (http://on.wsj.com/1VR4A2v) Further company coverage:    (Bengaluru Newsroom) 
V,BRIEF-Visa Co, Visa Europe enter amended and restated transaction agreementBRIEF-Wal-Mart sues Visa over chip-enabled debit card transactions- WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.  Wal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores. * Wal- Mart filed a lawsuit against Visa saying payments network is preventing  it from requiring customers to verify their purchases -WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.   BRIEF-Wal-Mart sues Visa over chip-enabled debit card transactions- WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.  Wal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores. * Wal- Mart filed a lawsuit against Visa saying payments network is preventing  it from requiring customers to verify their purchases -WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.  * Co, Visa Europe entered into an amended and restated transaction agreementBRIEF-Wal-Mart sues Visa over chip-enabled debit card transactions- WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.  Wal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores. * Wal- Mart filed a lawsuit against Visa saying payments network is preventing  it from requiring customers to verify their purchases -WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.   
WMT,BRIEF-Wal-Mart sues Visa over chip-enabled debit card transactions- WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.  Wal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores. * Wal- Mart filed a lawsuit against Visa saying payments network is preventing  it from requiring customers to verify their purchases -WSJWal-Mart sues Visa for resisting use of PIN-based transactions May 10 Wal-Mart Stores Inc filed a lawsuit against Visa Inc, saying the payments network operator was resisting the use of personal identification numbers (PINs) by customers for purchases made on debit cards at its stores.  
WFC,MOVES-Wells Fargo names Dreyer head of IG loan syndications LONDON, May 10 (IFR) - Wells Fargo has hired former Bank of America Merrill Lynch banker Shaun Dreyer to head its investment-grade loan syndications business. 
WDC,BRIEF-Western Digital acquisition of Sandisk receives approval from China's Ministry Of Commerce * Western Digital expects transaction to close on Thursday, May 12, 2016 
